your post veers into libel territory. Phase 1 trials test safety, not efficacy—tumor outcomes aren’t the yardstick here, and you know it’s early-stage. MK’s silence on full 30-day data doesn’t mean failure; it’s standard for safety monitoring to take time. Suggesting he’s ‘sitting on bad news’ based on one anecdote twists the truth into something damaging. Vivos reported on December 23rd: five patients treated, recovering well, gel placed perfectly. Implying otherwise without evidence isn’t just speculation—it’s reckless and smears MK and the trial unfairly.
Market Data 
Markets 
AI
